A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Daratumumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]